FDA approves Lundbeck’s Vyepti

A preventive treatment for adults with migraine will be available in April. Lundbeck has received the Food and Drug Administration’s blessing for Vyepti (eptinezumab-jjmr).

Vyepti is the first and only intravenous preventive treatment for migraine.

Deborah Dunsire, Lundbeck’s president and CEO said, “With the approval of Vyepti, I am pleased that we are now able to offer a new IV therapy that achieves the key treatment goal of preventing migraine over time while also delivering on the need for earlier onset of efficacy. The Vyepti clinical program is the first to demonstrate this early benefit.”

Migraine is a complex and incapacitating neurological disease characterized by recurrent episodes of severe headaches typically accompanied by an array of symptoms, including nausea, vomiting, and sensitivity to light or sound.